Document Detail

Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
MedLine Citation:
PMID:  9310955     Owner:  NLM     Status:  MEDLINE    
In this study, we demonstrate that immunostaining with MIB-1 and anti-bcl-2 is a useful tool to distinguish compound Spitz nevi from malignant melanomas. Forty-six cases of Spitz nevi and 50 cases of vertical growth-phase melanomas (Clark III-V) were compared for the immunoreactivity of MIB-1 and bcl-2 in the intradermal component of the lesions. As many as 76% of the Spitz nevus cases showed a low percentage (0-2%) of MIB-1 immunoreactivity. In the malignant melanomas, such a low MIB-1 index was shown in only 2% of the cases. The average MIB-1 index in malignant melanomas and Spitz nevi was 29.7 and 4.0%, respectively. bcl-2 was negative in only 4% of the melanoma cases, whereas the corresponding value was 72% in Spitz nevi. Statistical analyses using Students t test showed that the differences were highly significant (P < 0.001). By considering the immunoreactivity for MIB-1 and bcl-2 in the individual cases, we found that as many as 96% of the melanomas both expressed a bcl-2 positivity and exhibited a MIB-1 index exceeding 2% in the dermal component. The corresponding value was as low as 6% in the Spitz nevi.
L Kanter-Lewensohn; M A Hedblad; J Wejde; O Larsson
Related Documents :
6756665 - Sarcomas of the mouth and jaws--a study of 16 autopsy cases.
19766005 - Malignant fibrous histiocytosis after high-dose proton radiation therapy for anaplastic...
233365 - Malignant fibrous histiocytoma of bone.
6694825 - Malignant melanoma metastatic to the endometrium.
16142545 - Metanephric adenoma of the kidney: case report and review of the literature.
12058485 - Presenting signs of retinoblastoma in congolese patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc     Volume:  10     ISSN:  0893-3952     ISO Abbreviation:  Mod. Pathol.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-11-06     Completed Date:  1997-11-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8806605     Medline TA:  Mod Pathol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  917-20     Citation Subset:  IM    
Department of Tumor Pathology, Karolinska Institutet, Stockholm, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, Nuclear
Ki-67 Antigen
Melanoma / chemistry*
Nevus, Epithelioid and Spindle Cell / chemistry*
Nuclear Proteins / analysis*
Proto-Oncogene Proteins c-bcl-2 / analysis*
Skin Neoplasms / chemistry*
Tumor Markers, Biological / analysis
Tumor Suppressor Protein p53 / analysis
Reg. No./Substance:
0/Antigens, Nuclear; 0/Ki-67 Antigen; 0/Nuclear Proteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/Tumor Markers, Biological; 0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myxoid and sclerosing sarcomatoid transitional cell carcinoma of the urinary bladder: a clinicopatho...
Next Document:  Apoptosis in human pituitary adenomas: a morphologic and in situ end-labeling study.